
About us
EviCure is a pre-clinical stage biopharmaceutical company, leveraging AI and sophisticated experimental disease models for developing extracellular vesicle (EV) -based therapies for cancer.
The company platform consists of extracellular vesicles with inherent anti-tumor abilities combined with targeted delivery capabilities of different types of therapeutics.
Identification of extracellular vesicle subpopulations with specific activities
Using EVs for targeted delivery of different types of drugs and treatments
Novel scale-up technologies

EviCure's Technologies
Identification of EV subpopulations with specific activities
Novel scale-up technologies for generation of consistent and defined therapeutic EVs
EVs for targeted delivery of different types of drugs and treatments
AI-based scale up platform


Introducing AI precision into every step of the development process

Discovering the hidden molecular mechanisms of stem cells and their secreted EVs

Identifying EV subpopulations with selective tropism and therapeutic effects using human tumor models and humanized animal models

Precise scale-up production of EVs via real-time monitoring and AI analysis

Translating animal model results to humans – increasing prediction validity and applicability for clinical trials
Our Team

Eric J. Messika
Ph.D. MBA, CEO
Brings over 25 years of experience as an entrepreneur, angel investor, senior executive, and director in numerous early-stage biotech companies.
He has a Ph.D. in immunology from the Hebrew University and was an HHMI research associate at Stanford University.

Aharon Brodie
Ph.D. CTO
PhD in bioinformatics. Data science experience in the fields of Bioinformatics and Computer
Science. Data analysis in cancer therapeutics, anti-aging, and
degenerative diseases. Patents and publications related to big data and disease analysis.

Chaya Brodie
Ph.D. Consultant
Professor in the Faculty of Life Sciences and the Nanotechnology Center, Bar-Ilan University. Extensive research experience in cell and molecular biology and the areas of cancer, stem cells, and extracellular vesicles